

Title (en)

COMBINATION CONTAINING SGC ACTIVATORS AND MINERALOCORTICOID RECEPTOR ANTAGONISTS

Title (de)

KOMBINATION ENTHALTEND SGC AKTIVATOREN UND MINERALOCORTICOID-REZEPTOR-ANTAGONISTEN

Title (fr)

COMBINAISON CONTENANT DES ACTIVATEURS GCS ET DES ANTAGONISTES DU RÉCEPTEUR DES MINÉRALOCORTICOÏDES

Publication

EP 3525778 A1 20190821 (DE)

Application

EP 17777302 A 20171005

Priority

- EP 16193367 A 20161011
- EP 2017075356 W 20171005

Abstract (en)

[origin: WO2018069148A1] The invention relates to the combination of activators of soluble guanylate cyclase (sGC activators) with mineralocorticoid receptor antagonists (MR antagonists) and to the use of the combination to treat and/or prevent cardiac and cardiovascular diseases, renal and cardiorenal diseases, pulmonary and cardiopulmonary disease, and to treat and/or prevent fibrotic diseases.

IPC 8 full level

A61K 31/167 (2006.01); **A61K 31/4365** (2006.01); **A61K 45/06** (2006.01)

CPC (source: EP US)

A61K 31/167 (2013.01 - EP US); **A61K 31/192** (2013.01 - EP US); **A61K 31/4365** (2013.01 - EP US); **A61K 31/4375** (2013.01 - EP US);
A61K 45/06 (2013.01 - EP US); **A61P 9/00** (2017.12 - EP US); **A61P 11/00** (2017.12 - EP US); **A61P 13/12** (2017.12 - EP US)

Citation (search report)

See references of WO 2018069148A1

Designated contracting state (EPC)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Designated extension state (EPC)

BA ME

DOCDB simple family (publication)

WO 2018069148 A1 20180419; CA 3039735 A1 20180419; CN 109890379 A 20190614; EP 3525778 A1 20190821; JP 2019529521 A 20191017;
JP 7237823 B2 20230313; US 11331308 B2 20220517; US 2019224176 A1 20190725; US 2022241255 A1 20220804

DOCDB simple family (application)

EP 2017075356 W 20171005; CA 3039735 A 20171005; CN 201780062617 A 20171005; EP 17777302 A 20171005;
JP 2019519234 A 20171005; US 201716337020 A 20171005; US 202217723045 A 20220418